Valspodar: current status and perspectives

Bibliography

• GUPTA S, TSURUO T: Multidrug Resistance in Cancer Cells. (1996) John Wiley & Sons Ltd.
   Google Scholar
• JETTE L, POTTER M, BELIVEAU R: P-glycoprotein is a dimer in the kidney and brain capillary membranes: effect of cyclosporin A and SDZ-PSC 833. Biochemistry (1997) 36:13929–13937.
   PubMed Web of Science ®Google Scholar
• SHAROM FJ, YU X, CHU JWK, DOIGE CA: Characteriza-tion of the ATPase activity of P-glycoprotein from multidrug-resistant chinese hamster ovary cells. Biochem. J. (1995) 308:381–390.
   PubMed Web of Science ®Google Scholar
• SIMONS K, IKONEN E: Functional rafts in cell membranes. Nature (1997) 387:569–572.
   PubMed Web of Science ®Google Scholar
• HIGGINS CF: Flip-flop: the transmembrane transloca-tion of lipids. Cell (1994) 79:393–395.
   PubMedGoogle Scholar
• CULLIS PR, HOPE MJ, BALLY MB, MADDEN TD, MAYER LD, FENSKE DB: Influence of pH gradients on the transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim. Biophys. Acta (1997) 1331:187–211.
   PubMed Web of Science ®Google Scholar
• FAHR A: Cyclosporin clinical pharmacokinetics. Clin. Pharmacokin. (1993) 24:472–495.
   PubMed Web of Science ®Google Scholar
• THUMMEL KE, WILKINSON GR: In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. Toxicol. (1998) 38:389–430.
   PubMed Web of Science ®Google Scholar
• SILVERMAN JA, SCHRENK D: Expression of the multidrug resistance genes in the liver. FASEB J (1997) 11:303–313.
   Google Scholar
• SIKIC BI, FISHER GA, LUM BL, HALSEY J, BEKETIC-ORESKOVIC L, CHEN G: Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother. Pharmacol. (1997) 40:S13–19.
   PubMed Web of Science ®Google Scholar
• LOOR F: Cyclosporins and related fungal products in the reversal of P-glycoprotein-mediated multidrug resistance. In: Multi-drug resistance in Cancer Cells. Gupta S & Tsuruo T (Eds.), John Wiley & Sons Ltd. (1996) :387–412.
   Google Scholar
• ••A general review of their in vitro and preclinical in vivochemosensitising features.
   Google Scholar
• LEE CG, GOTTESMAN MM, CARDARELLI CO et al.: 111V-1 inhibitors are substrates for the MDR 1 multidrug transporter. Biochemistry (1998) 37:3594–3601.
   PubMed Web of Science ®Google Scholar
• LEE CGL, GOTTESMAN MM: 11IV-1 protease inhibitors the MDR 1 multidrug transporter. J. Clin. Invest. (1998) 101:287–288.
   PubMed Web of Science ®Google Scholar
• ••An editorial on the risks and potential of blood-brain barrierneutralisation strategies.
   Google Scholar
• KIM RB, FROMM MF, WANDEL C et al.: The drug transporter P-glycoprotein limits oral absorption and brain entry of 11IV-1 protease inhibitors. J. Clin. Invest. (1998) 101:189–194.
   Google Scholar
• FISHER GA, SIKIC BI: Clinical studies with modulators of multidrug resistance. Drug-resist. Clin. Oncol. Haematol. (1995) 9:363–382.
   PubMed Web of Science ®Google Scholar
• SIKIC BI: Pharmacologic approaches to reversing multidrug resistance. Semin. Hematol (1997) 34:40–47.
   PubMed Web of Science ®Google Scholar
• ••A clinical review of valspodar, including its potentialprophylactic use in cancer.
   Google Scholar
• ROBERT J: Approaches to multidrug resistance reversal. Exp. Opin. Invest. Drugs (1998) 7:929–939.
   PubMedGoogle Scholar
• SAMUELS BL, HOLLIS DR, ROSNER GL et al.: Modulationof vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study. Clin. Cancer Res. (1997) 3:1977–1984.
   PubMed Web of Science ®Google Scholar
• GAVERIAUX C, BOESCH D, BOELSTERLI JJ et al.:Overcoming multidrug-resistance in Chinese hamster ovary cells in vitro by cyclosporin A (Sandimmune®) and non-immunosuppressive derivatives. Br. J. Cancer (1989) 60:867–871.
   PubMed Web of Science ®Google Scholar
• GAVERIAUX C, BOESCH D, JACHEZ B, BOLLINGER P, PAYNE T, LOOR F: SDZ PSC-833, a non- immunosup-pressive cyclosporin analog, is a very potent-resistance modifier. J. Cell Pharmacol. (1991) 2:225–234.
   Google Scholar
• •The first description of valspodar, the reprints of which are still available from this author.
   Google Scholar
• JACHEZ B, NORDMANN R, LOOR F: Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446.1 Natl. Cancer Inst. (1993) 85:478–483.
   PubMed Web of Science ®Google Scholar
• BOLLINGER P, BOLSTERLI JJ, BOREL JF et al.: Cyclosporins and their use as pharmaceuticals. (Sandoz AG; Sandoz Patent GmbH; Sandoz Erfindungen GmbH). AU 8817679, EP 296122, JP 89045396.
   Google Scholar
• TIBERGHIEN F, DIDIER A, LOOR F: Structure-activity relationships of macrolides for the inhibition of MDR1 P-glycoprotein function, as determined by the calcein-AM efflux method. Unpublished data, manuscript on hold (1997).
   Google Scholar
• POHL E, HERBST-IRMER R, SHELDRICK GM et al: Crystal structures of two modifications of [3,0-didehydro-MeBmt, Val]-cyclosporin and comparison of three different X-ray data sets. Helv. Chim. Acta (1995) 78:355–366.
   Web of Science ®Google Scholar
• SHAW RA, MANTSCH HH, CHOWDHRY BZ: Solvent influence on the conformation of cyclosporin. An FT-IR study. Can. J. Chem. (1993) 71:1334–1339.
   Web of Science ®Google Scholar
• EL TAYAR N, MARK AE, VALLAT P, BRUNNE RM, TESTA B,VAN GUNSTEREN WF: Solvent-dependent conforma-tion and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations. J. Med. Chem. (1993) 36:3757–3764.
   PubMed Web of Science ®Google Scholar
• SCOTT MG, HOCK KG, CRIMMINS DL, FRACASSO PM: HPLC method for monitoring SDZ PSC 833 in whole blood. Clin. Chem. (1997) 43:505–510.
   PubMed Web of Science ®Google Scholar
• BOOTE DJ, DENNIS IF, TWENTYMAN PR et al.: Phase Istudy of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J. Clin. Oncol. (1996) 14:610–618.
   PubMed Web of Science ®Google Scholar
• LEHNERT M, PFISTER M, RUSSEL DA, BALL HA: Validation of rhodamine 123 bioassay for monitoring SDZ PSC 833 serum levels in humans. Proc. Am. Ass. Cancer Res. (1998) 39:326.
   Google Scholar
• LUSH RM, MEADOWS B, FOJO AT et al.: Initial pharma-cokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist. J. Clin. Pharmacol. (1997) 37:123–128.
   PubMed Web of Science ®Google Scholar
• MUELLER EA, KOVARIK JM, URESIN Y et al.: Optimizing the absorption of valspodar, a P-glycoprotein modulator, Part I: Selecting an oral formulation and exploring its clinical pharmacokinetics/dynamics. Clin. Pharmacol. (1997) 37:1001–1008.
   Google Scholar
• ERLICHMAN C, MOORE MJ, DE ANGELIS G, GOODMAN P, MANZO J: The pharmacokinetics and bioavailability of a new chemosensitizer, SDZ PSC 833, in patients with advanced cancer. Anti-Cancer Drugs (1994) 5:44.
   Google Scholar
• KOVARIK JM, MUELLER EA, RICHARD F, TETZLOFF W:Optimizing the absorption of valspodar, a-glycoprotein modulator, Part II: Quantifying its pharmacokinetic variability and refining the bioavail-ability estimate. J. Gun. Pharmacol. (1997) 37:1009–1014
   Google Scholar
• ••The complete description of valspodar pharmacokineticsfor the clinician.
   Google Scholar
• KORNBLAU SM, ESTEY E, MADDEN T et al: Phase I studyof mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J. Clin. Oncol. (1997) 15:1796–1802.
   PubMed Web of Science ®Google Scholar
• TOFFOLI G, CORONA G, SORIO R, BERTOLA A, BOIOCCHI M: Reversal activity of cyclosporin A and its metabolites Ml, M17 and M21 in multidrug-resistant cells. Int. J. Cancer (1997) 71:900–906.
   PubMed Web of Science ®Google Scholar
• FISCHER V, RODRIGUEZ-GASCON A, HEITZ F et al.: The multidrug resistance modulator Valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharma-cological activity of the main metabolite. Drug Metab. Disp. (1998) 26:802–811.
   Web of Science ®Google Scholar
• ••The latest data on valspodar metabolisation by CYP3A andits consequences.
   Google Scholar
• HOLT DW, JOHNSTON A, ROBERTS NB, TREDJER JM, TRULL AK: Methodological and clinical aspects of cyclosporine monitoring: report of the Association of Clinical Biochemist task force. Ann. Clin. Biochem. (1994) 31:420–446.
   PubMed Web of Science ®Google Scholar
• YATSCOFF RW, COPELAND KR, FARACI CJ: Abbott TDxmonoclonal antibody assay evaluated for measuring cyclosporine in whole blood. Clin. Chem. (1990) 36:1969–1973.
   PubMed Web of Science ®Google Scholar
• DIDIER A, WENGER J, LOOR F: Decreased uptake ofcyclosporin A by P-glycoprotein (Pgp) expressing CEM leukemic cells and restoration of normal retention by Pgp blockers. Anti-Cancer Drugs (1995) 6:669–680.
   PubMed Web of Science ®Google Scholar
• DEMEULE M, WENGER RM, BELIVEAU R: Molecular interactions of cyclosporin A with P-glycoprotein. Photolabeling with cyclosporin derivatives. J. Biol. Chem. (1997) 272:6647–6652.
   PubMedGoogle Scholar
• •An elegant study on the interactions of cyclosporins and P-glycoproteins.
   Google Scholar
• BOSCH I, DUNUSSI-JOANNOPOULOS K, WU RL, FURLONG ST, CROOP J: Phosphatidylcholine and phosphatidylethanolamine behave as substrates of the human MDR1 P-glycoprotein. Biochemistry (1997) 36:5685–5694.
   PubMed Web of Science ®Google Scholar
• TIBERGHIEN F, LOOR F: Ranking of P-glycoproteinsubstrates and inhibitors by a calcein-AM fluorometry screening assay. Anti-Cancer Drugs (1996) 7:568–578.
   PubMed Web of Science ®Google Scholar
• •A method used to measure inhibition of Pgp function by 1001 potential substrates.
   Google Scholar
• SMITH AJ, MAYER U, SCHINKEL AH, BORST P: Availability of PSC 833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum. J. Natl. Cancer Inst. (1998) 90:1161–1166.
   PubMed Web of Science ®Google Scholar
• ••A challenge to the in vivo potential of valspodar.
   Google Scholar
• BARRAND MA, RHODES T, CENTER MS, TWENTYMAN PR: and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein. Eur. J. Cancer (1993) 29A:408–415.
   PubMed Web of Science ®Google Scholar
• BOREL JF, BAUMANN G, CHAPMAN I et al.: In vivo pharmacological effects of ciclosporin and some analogues. Advan. Pharmacol. (1996) 35:115–246.
   PubMedGoogle Scholar
• KEPPLER D, ARIAS IM: Hepatic canalicular membrane: Introduction: Transport across the hepatocyte canalicular membrane. FASEB J (1997) 11:15–18.
   PubMed Web of Science ®Google Scholar
• KOEPSELL H: Organic cation transporters in intestine, kidney, liver and brain. Annu. Rev. Physiol. (1998) 60:243–266.
   PubMed Web of Science ®Google Scholar
• LEIER I, JEDLITSCHKY G, BUCHHOLZ U, COLE SP,DEELEY RG, KEPPLER D: The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J. Biol. Chem. (1994) 269:27807–27810.
   PubMed Web of Science ®Google Scholar
• BOHME M, JEDLITSCHKY G, LEIER I, BUCHLER M, KEPPLER D: ATP-dependent export pumps and their inhibition by cyclosporins. Adv. Enz. Regul (1994) 34:371–380.
   PubMedGoogle Scholar
• BOHME M, MULLER M, LEIER I, JEDLITSCHKY G, KEPPLER: Cholestasis caused by inhibition of the adenosine triphosphate-dependent bile salt transport in rat liver. Gastroenterology (1994) 107:255–265.
   PubMed Web of Science ®Google Scholar
• LEIER I, JEDLITSCHKY G, BUCHHOLZ U, KEPPLER D: Characterization of the ATP-dependent leukotriene C4 export carrier in mastocytoma cells. Eur. J. Biochem. (1994) 220:599–606.
   PubMedGoogle Scholar
• BOHME M, BUCHLER M, MULLER M, KEPPLER D: Differ-ential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane. FEBS Lett. (1993) 333:193–196.
   PubMed Web of Science ®Google Scholar
• EVERS R, KOOL M, VAN DEEMTER L et al.: Drug export activity of the human canalicular multispecifi organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J. Clin. Invest. (1998) 101:1310–1319.
   Google Scholar
• VAN HELVOORT A, SMITH AJ, SPRONG H et al.: MDR1P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell (1996) 87:507–517.
   PubMed Web of Science ®Google Scholar
• LEMAIRE M, BRUELISAUER A, GUNTZ P, SATO H: Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin, in rats. Cancer Chemother. Pharmacol. (1996) 38:481–486.
   PubMed Web of Science ®Google Scholar
• •The evidence for brain uptake of valspodar.
   Google Scholar
• DESRAYAUD S, DE LANGE EC, LEMAIRE M, BRUELISAUER, DE BOER AG, BREIMER DD: Effect of the Mdrla P-glycoprotein gene disruption on the tissue distribu-tion of SDZ PSC 833, a multidrug resistance-reversing agent, in mice. J. Pharmacol. Exp. Ther. (1998) 285:438–443
   PubMed Web of Science ®Google Scholar
• LO RUSSO A, PASSAQUIN AC, ANDRE P, SKUTELLA M,RUEGG UT: Effect of cyclosporin A and analogues on cytosolic calcium and vasoconstriction: possible lack of relationship to immunosuppressive activity. Br. J. Pharmacol. (1996) 118:885–892.
   PubMed Web of Science ®Google Scholar
• LO RUSSO A, PASSAQUIN AC, COX C, RCJEGG UT: Cyclosporin A potentiates receptor-activated [Ca21c increase. J. Recept. Signal Transduct. Res. (1997) 17:149–161.
   PubMed Web of Science ®Google Scholar
• WENZEL-SEIFERT K, SEIFERT R: Cyclosporin H is apotent and selective formyl peptide receptor antago-nist. Comparison with N-t-butoxycarbonyl-L-phenylalanyl-L-leucyl-L-phenylalanyl-L-leucyl-L-phenylalanine and cyclosporins A, B, C, D, and E. J. Immunol. (1993) 150:4591–4599.
   Google Scholar
• DE PAULIS A, CICCARELLI A, DE CRESCENZO G, CIRILLOR, PATELLA V, MARONE G: Cyclosporin H is a potent and selective competitive antagonist of human basophil activation by N-formyl-leucyl-phenylalanine. J. Allergy Clin. Immunol. (1996) 98:152–164.
   PubMed Web of Science ®Google Scholar
• TIBERGHIEN F, TRABER R, DIDIER A, LOOR F: Cyclosporin-mediated inhibition of model 7TM G-protein coupled receptor and 12TM ABC-transporter. Structure-Activity Relationships. (1999) (Manuscript in preparation).
   Google Scholar
• LEITNER I, RYDER N: Antifungal activity in vitro of SDZ PSC 833 in comparison with cyclosporin A. Novartis Pharma. Ltd. (1996) RDS file PKF–96–01641.
   Google Scholar
• POURTIER-MANZANEDO A, DIDIER A, LOOR F: Expres-sion of P-glycoprotein on normal lymphocytes: enhancement of the doxorubicin-sensitivity of concanavalin A-responding mouse spleen cells by P-glycoprotein blockers. Oncol. Res. (1992) 4:473–480.
   PubMed Web of Science ®Google Scholar
• DIDIER A, LOOR F: Enhancement of the cyclosporin A-mediated inhibition of concanavalin A-induced mouse spleen cell proliferation by the P-glycoprotein blocker SDZ 280-446. Cell. Pharmacol. (1995) 2:59–67.
   Google Scholar
• QUESNIAUX V, MAURER C: Binding of PSC 833 to cyclophilins A, B and C. Novartis Pharma. Ltd. (1995) RDS file PKF–95–01702.
   Google Scholar
• SNYDER SH, SABATINI DM, LAI MM, STEINER JP,HAMILTON GS, SUZDAK PD: Neural actions of immuno-philin ligands. Trends Pharmacol. Sci. (1998) 19:21–26.
   PubMed Web of Science ®Google Scholar
• LIU JP, SIM ATR, ROBINSON PJ: Calcineurin inhibition ofdynamin 1 GTPase activity coupled to nerve terminal depolarization. Science (1994) 265:970–973.
   PubMed Web of Science ®Google Scholar
• SCHNEIDER H, CHARARA N, SCHMITZ R et al.: Human cyclophilin C: Primary structure, tissue distribution and determination of binding specificity for cyclosporins. Biochemistry (1994) 33:8218–8224.
   PubMed Web of Science ®Google Scholar
• VICKERS AEM, ALEGRET M, JIMENEZ RM et al.: Changes in human liver and kidney slice function related to potential side-effects in the presence of biotransfor-mation of four cyclosporin derivatives - CsA, IMM, OG, and PSC. In Vitro Mol Toxicol. (1998) 11:119–132.
   Google Scholar
• JANOWSKI B, FISCHER G: Modulation of cyclosporin AlCyclophilin interactions by drug vehicles. Bioorgan. Med. Chem. (1997) 5:179–186.
   PubMed Web of Science ®Google Scholar
• WATANABE T, KOKUBU N, CHARNICK SB, NAITO M, TSURUO T, COHEN D: Interaction of cyclosporin derivatives with the ATPase activity of human P-glycoprotein. Br. J. Pharmacol (1997) 122:241–248.
   PubMed Web of Science ®Google Scholar
• BOESCH D, MULLER K, POURTIER-MANZANEDO A, LOORF: Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Exp. Cell Res. (1991) 196:26–32.
   PubMed Web of Science ®Google Scholar
• POURTIER-MANZANEDO A, DIDIER AD, MULLER CD, LOOR F: SDZ PSC 833 and SDZ 280-446 are the most active of various resistance-modifying agents in restoring rhodamine-123 retention within multidrug resistant P388 cells. Anti-Cancer Drugs (1992) 3:419–425.
   PubMed Web of Science ®Google Scholar
• DIDIER A, TIBERGHIEN F, WENGER R, LOOR F: Detectionof P-glycoprotein expression by tumoral cells with NBDL-CsA, a fluorescent derivative of cyclosporin A. Anti-Cancer Drugs (1996) 7:257–265.
   PubMed Web of Science ®Google Scholar
• LIMINGA G, NYGREN P, LARSSON R: Microfluorometricevaluation of calcein acetoxymethyl ester as a probe for P-glycoprotein-mediated resistance: effects of cyclosporin A and its nonimmunosuppressive analogue SDZ PSC 833. Exp. Cell Res. (1994) 212:291–296.
   PubMed Web of Science ®Google Scholar
• PIWNICA-WORMS D, RAO VV, KRONAUGE JF, CROOP JM:Characterization of multidrug resistance P-glycoprotein transport function with an organo-technetium cation. Biochemistry (1995) 34:12210–12220.
   PubMed Web of Science ®Google Scholar
• BALLINGER JR, BANNERMAN J, BOXEN I, FIRBY P,HARTMAN NG, MOORE MJ: Technetium-99m-tetrofosmin as a substrate for P-glycoprotein: In vitro studies in multidrug-resistant breast tumor cells. J. Nucl. Med. (1996) 37:1578–1582.
   PubMed Web of Science ®Google Scholar
• BALLINGER JR, HUA HA, BERRY BW, FIRBY P, BOXEN I:(99)Tc(m)-sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance: In vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant. Nucl. Med. Commun. (1995) 16:253–257.
   PubMed Web of Science ®Google Scholar
• ARCHINAL-MATTHEIS A, RZEPKA RW, WATANABE T et al.: Analysis of the interactions of SDZ PSC 833 ([3'-keto-Bmtl]-Va121-Cyclosporine), a multidrug resistance modulator, with P-glycoprotein. Oncol. Res. (1995) 7:603–610.
   PubMed Web of Science ®Google Scholar
• NAITO M, WATANABE T, TSUGE H, KOYAMA T, OH HARAT, TSURUO T: Potentiation of the reversal activity of SDZ PSC833 on multi-drug resistance by an anti-P-glycoprotein monoclonal antibody MRK-16. Int. J. Cancer (1996) 67:435–440.
   PubMed Web of Science ®Google Scholar
• GOLDBERG H, LING V, WONG PY, SKORECKI K: Reducedcyclosporin accumulation in multidrug-resistant cells. Biochem. Biophys. Res. Comm. (1988) 152:552–558.
   PubMed Web of Science ®Google Scholar
• BOESCH D, LOOR F: Extent and persistence of-glycoprotein inhibition in multidrug-resistant P388 cells after exposure to resistance-modifying agents. Anti-Cancer Drugs (1994) 5:229–238.
   PubMed Web of Science ®Google Scholar
• •The first evidence for the persistence of Pgp inhibition by valspodar.
   Google Scholar
• DIDIER A, LOOR F: The abamectin derivative ivermectin is a potent P-glycoprotein inhibitor. Anti-Cancer Drugs (1996) 7:745–751.
   PubMed Web of Science ®Google Scholar
• JACHEZ B, CIANFRIGLIA M, LOOR F: Modulation of human P-glycoprotein epitope expression by temperature and/or resistance-modulating agents. Anti-Cancer Drugs (1994) 5:655–665.
   PubMed Web of Science ®Google Scholar
• •Data suggesting the occurrence of inactive Pgp conformers.
   Google Scholar
• HORTON JK, THIMMAIAH KN, ALTENBERG GA et al: Characterization of a novel bisacridone and comparison with PSC 833 as a potent and poorly reversible modulator of P-glycoprotein. Mol. Pharmacol. (1997) 52:948–957.
   PubMed Web of Science ®Google Scholar
• KRISHNA R, DE JONG G, MAYER LD: Pulsed exposure of SDZ PSC 833 to multidrug resistant P388/ADR and MCF7/ADR cells in the absence of anticancer drugs can fully restore sensitivity to doxorubicin. Anti-Cancer Res. (1997) 17:3329–3334.
   PubMed Web of Science ®Google Scholar
• JETTE L, MURPHY GF, BELIVEAU R. Modification of P-glycoprotein expression and drug binding in normal tissues following PSC-833 treatment. Proc. Am. Assoc. Cancer Res. (1997) 38:594.
   Google Scholar
• JETTE L, MURPHY GF, BELIVEAU R: Drug binding to P-glycoprotein is inhibited in normal tissues following SDZ-PSC 833 treatment. Int. J. Cancer (1998) 76:729–737
   PubMed Web of Science ®Google Scholar
• •Data interpretable as valspodar-mediated recruitment of inactive Pgp conformers.
   Google Scholar
• AUGUSTIJNS PF, BRADSHAW TP, GAN LSL, HENDREN RW, DR: Evidence for a polarized efflux system in caco-2 cells capable of modulating cyclosporin A transport. Biochem. Biophys. Res. Comm. (1993) 197:360–365.
   PubMed Web of Science ®Google Scholar
• HU YP, CHAPEY C, ROBERT J: Relationship between the inhibition of azidopine binding to P-glycoprotein by MDR modulators and their efficiency in restoring doxorubicin intracellular accumulation. Cancer Lett. (1996) 109:203–209.
   PubMed Web of Science ®Google Scholar
• JETTE L, BEAULIEU E, LECLERC JM, BELIVEAU R: Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues. Am. J. Physiol. (1996) 270:F756–765.
   PubMed Web of Science ®Google Scholar
• BOER R, ULRICH WR, HAAS S et al.: Interaction of cytostatics and chemosensitizers with the dexniguldipine binding site on P-glycoprotein. Eur. J. Pharmacol. (1996) 295:253–260.
   PubMed Web of Science ®Google Scholar
• FOXWELL BMJ, MACKIE A, LING V, RYFFEL B: Identifica-tion of the multidrug resistance-related P-glycoprotein as a cyclosporin binding protein. Mol. Pharmacol (1989) 36:543–546.
   PubMedGoogle Scholar
• RYFFEL B: Personal communication, unpublished data(1990).
   Google Scholar
• BECK-SICKINGER AG: Structural characterization and binding sites of G-protein-coupled receptors. Drug Dev. Today (1996) 1:502–513.
   Web of Science ®Google Scholar
• GUDERMANN T, KALKBRENNER F, SCHULTZ G: Diversity and selectivity of receptor-G-protein interaction. Annu. Rev. Pharmacol. Toxicol. (1996) 36:429–459.
   PubMed Web of Science ®Google Scholar
• BOESCH D, GAVERIAUX C, JACHEZ B, POURTIER-MANZANEDO A, BOLLINGER P, LOOR F: In vivo circum-vention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res. (1991) 51:4226–4233.
   PubMed Web of Science ®Google Scholar
• •First preclinical evidence for valspodar activity in vivo.
   Google Scholar
• LOOR F, BOESCH D, GAVERIAUX C, JACHEZ B, POURTIER-MANZANEDO A, EMMER G: SDZ 280–446, a novel semi-synthetic cyclopeptolide: in vitro and in vivo circumvention of the P-glycoprotein-mediated tumour cell multidrug resistance. Br. 1Cancer (1992) 65:11-18. and BOESCH D, JACHEZ B, LOOR F: Multi-drug resistance modulating agents: Comparisons of the in vivo chemotherapy performances of SDZ PSC 833 and SDZ 280–446. PKF DAT/MRGI report 20-10–1992.
   Google Scholar
• KELLER RP, ALTERMATT HJ, NOOTER K et al.: SDZ PSC833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia. Int. J. Cancer (1992) 50:593–597.
   PubMed Web of Science ®Google Scholar
• WATANABE T, TSUGE H, OH HARA T, NAITO M, TSURUO T: Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol. (1995) 34:235–241.
   PubMed Web of Science ®Google Scholar
• WATANABE T, NAITO M, OH HARA T, ITOH Y, COHEN D, TSURUO,T: Modulation of multidrug resistance by SDZ PSC 833 in leukemic and solid-tumor-bearing mouse models. Jpn. J. Cancer Res. (1996) 87:184–193.
   PubMedGoogle Scholar
• KELLER RP, ALTERMATT HJ, DONATSCH P, ZIHLMANN H, LAISSUE JA, HIESTAND PC: Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity. Int. J. Cancer (1992) 51:433–438.
   PubMed Web of Science ®Google Scholar
• GONZALEZ 0, COLOMBO T, DE FUSCO M, IMPERATORI, ZUCCHETTI M, D'INCALCI M: Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833. Cancer Chem other. Pharmacol. (1995) 36:335–340.
   PubMed Web of Science ®Google Scholar
• COLOMBO T, GONZALEZ-PAZ 0, D'INCALCI M: Distribu-tion and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia. Br. J. Cancer (1996) 73:866–871.
   PubMed Web of Science ®Google Scholar
• CHEN CC, MEADOWS B, REGIS J et al.: Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi. Clin. Cancer Res. (1997) 3:545–552.
   PubMed Web of Science ®Google Scholar
• CHICO I, MEADOWS B, FOJO A et al.: A Phase I trial of infusional vinblastine with the cyclosporine analog, PSC-833 in patients with metastatic cancer. Proc. Am. Assoc. Cancer Res. (1996) 37:166.
   Google Scholar
• BARBARICS E, KRONAUGE JF, COHEN D, DAVISON A, JONES AG, CROOP JM: Characterization of P-glycoprotein transport and inhibition in vivo. Cancer Res. (1998) 58:276–282.
   PubMed Web of Science ®Google Scholar
• KRISHNA R, MAYER LD: Liposomal doxorubicin circum-vents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors. Cancer Res. (1997) 57:5246–5253.
   PubMed Web of Science ®Google Scholar
• SONNEVELD P, MARIE JP, HUISMAN C et al.: Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A Phase I study. Leukemia (1996) 10:1741–1750.
   PubMed Web of Science ®Google Scholar
• CUFER T, VRHOVEC I, PFEIFER M, SHRK J, BORSTNAR S, SIKIC BI: Effects of the multidrug resistance modulator valspodar on serum cortisol levels in rabbits. Cancer Chemother. Pharmacol. (1998) 401:517–521.
   Google Scholar
• eRESIN Y, TETZLOFF W, ABOLIN C et al.: A study on the safety and tolerability of single rising doses of PSC 833 in healthy male volunteers. Sandoz Pharma Ltd., Basel Switzerland (1992):303–165.
   Google Scholar
• SIMON N, DAILLY E, COMNES 0, MALAURIE E, LEMAIRE, TILLEMENT JP. Role of lipoproteins in the plasma binding of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin. Br. J. Clin. Pharmacol (1998) 45:173–175.
   Google Scholar
• LUDESCHER C, EISTERER W, HILBE W, HOFMANN J, THALER J: Decreased potency of MDR-modulators under serum conditions determined by a functional assay. Br.J. HaemaL (1995) 91:652–657.
   PubMed Web of Science ®Google Scholar
• LEHNERT M, DE GIULI R, KUNKE K, EMERSON S, DALTON WS, SALMON SE: Serum can inhibit reversal of multidrug resistance by chemosensitisers. Eur. Cancer (1996) 32:862–867.
   Google Scholar
• FRICKER G, DREWE J, HUWYLER J, GUTMANN H, BEGLINGER C: Relevance of P-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br. J. Pharmacol (1996) 118:1841–1847.
   PubMed Web of Science ®Google Scholar
• GARATTINI S: Drug metabolism: From experiments to regulatory aspects. Drug Metab. Rev. (1997) 29:853–886.
   PubMed Web of Science ®Google Scholar
• GONZALES FJ, IDLE JR: Pharmacogenetic phenotyping and genotyping. Present status and future potential. Clin. Pharmacokinet. (1994) 26:59–70.
   PubMed Web of Science ®Google Scholar
• COVELLI A: SDZ PSC 833: un nuovo modulatore della MDR. Tumori (1997) 83:S2I–24.
   Google Scholar
• GAVERIAUX C, BOESCH D, LOOR F: Unpublished data, reported in successive internal Sandoz Pharma Ltd. files (1988); with summary by BOESCH D, LOOR F: Report on screening of cyclosporin derivatives for reversal of tumor cell multidrug resistance. PKF DAT/MRGI report 31-03–1994
   Google Scholar
• HAUCK C: Personal communication (1998) quoted in ref. 36.
   Google Scholar
• CHARUK JHM, WONG PY, REITHMEIER RAF: Differential interaction of human P-glycoprotein with various and analogues of cyclosporin A. Am. J. Physiol. (1995) 269:F31–39.
   PubMed Web of Science ®Google Scholar
• GAN LSL, MOSELEY MA, KHOSLA B et al.: CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. Drug Metab. Dispos. (1996) 24:344–349.
   PubMed Web of Science ®Google Scholar
• VAN DE VRIE W, JONKER AM, MARQUET RL, EGGERMONT AM: The chemosensitizer cyclosporin A enhances the toxic side-effects of doxorubicin in the rat. J. Cancer Res. Clin. Oncol. (1994) 120:533–538.
   PubMed Web of Science ®Google Scholar
• LYUBIMOV E, LAN LB, PASHINSKY I, STEIN WD: Effect of modulators of the multidrug resistance pump on the distribution of vinblastine in tissues of the mouse. Anti-Cancer Drugs (1996) 7:60–69
   PubMed Web of Science ®Google Scholar
• BARTLETT N, LUM BL, FISHER GA et al.: Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J. Clin. Oncol (1994) 12:835–842.
   PubMed Web of Science ®Google Scholar
• GIACCONE G, LINN SC, WELINK J et al.: A dose-finding and pharmacokinetics study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin. Cancer Res. (1997) 3:2005–2015.
   PubMed Web of Science ®Google Scholar
• FRACASSO PM, FISHER GA, WIEHL JG, COLLINS H, HAUSDORFF J, WILLIAMS KM. Phase I trial of paclitaxel (Taxol) and SDZ PSC 833 in patients with solid tumors. Proc. Am. Soc. Clin. Oncol (1995) 14:486.
   Google Scholar
• COLLINS HL, FISHER GA, HAUSDORFF J, LUM BL, PEARCE T, HALSEY J. Phase I trial of paclitaxel in combination with SDZ PSC 833, a multidrug resistance modulator. Proc. Am. Soc. Clin. Oncol (1995) 14:181.
   Google Scholar
• LUM BL, FISHER GA, HAUSDORF J, GOTTWALD M, COLLINS H, BROPHY NA. The effect of SDZ PSC 833, a cyclosporin D analog, on the pharmacokinetic behavior of etoposide (E) during a Phase I trial to modulate multidrug resistance. Clin. Pharmacol. Ther. (1995) 57:175.
   Web of Science ®Google Scholar
• HAUSDORFF J, FISHER GA, HALSEY J et al.: A Phase! trial of etoposide with the oral cyclosporin SDZ PSC 833, a modulator of multidrug resistance (MDR). Proc. Am. Soc. Clin. Oncol. (1995) 14:181.
   Google Scholar
• CHARNICK SB, FRACASSO P, EGORIN M et al.: Pharma-cokinetics (PK) and pharmacodynamics (PD) of SDZ PSC 833, a novel multidrug resistance reversing agent, in Phase 1 trials with chemotherapeutic agents. Eur. J. Cancer (1997) 33:S173.
   Google Scholar
• EGORIN M, FRACASSO P, ZUHOWSKI E, DANIEL F, KEARNS C, FISHER G. Effect of the MDR modulator, SDZ-PSC-833 on the pharmacokinetics (pk) and pharmacodynamics (pd) of 3h paclitaxel (OAC) infusions. Proc. Am. Soc. Clin. Oncol (1996) 15:473.
   Google Scholar
• HAUSDORFF J, FISHER GA, HALSEY J, MALLARINO MC, LUM BL, SIKIC BI. Doxorubicin, paclitaxel, and oral PSC 833, a modulator of multidrug resistance (MDR): a Phase I trial. Proc. Am. Soc. Clin. Oncol. (1996) 15:188.
   Google Scholar
• LIST A, SPIER C, KARANES C et al.: Phase I study of SDZ PSC-833 as a modulator of daunomycin in acute leukemia. Proc. Am. Assoc. Cancer Res. (1996) 37:167.
   Google Scholar
• SONNEVELD P, LOKHORST HM, VOSSEBELD P: Drug resistance in multiple myeloma. Semin. Hematol. (1997) 34:34–39.
   PubMed Web of Science ®Google Scholar
• •Phase I/II data on valspodar as adjunct to VAD treatment of multiple myeloma.
   Google Scholar
• FROIDEVAUX S, LOOR F: Myeloid and lymphoid cell alterations in normal mice exposed to chemotherapy with doxorubicin and/or the multidrug-resistance reversing agent SDZ PSC 833. Int. J. Cancer (1994) 59:133–140.
   PubMed Web of Science ®Google Scholar
• •Thorough analysis of the doxorubicin myelotoxicity profile with valspodar.
   Google Scholar
• POURTIER-MANZANEDO A, DIDIER A, FROIDEVAUX S, LOOR F: Lymphotoxicity and myelotoxicity of doxorubicin and SDZ PSC 833 combined chemothera-pies for normal mice. Toxicology (1995) 99:207–217.
   PubMed Web of Science ®Google Scholar
• SPEEG KV, MALDONADO AL, LIACI J, MUIRHEAD D: Effect of cyclosporin on colchicine secretion by the kidney multidrug transporter studied in vivo. J. Pharmacol. Exp. Ther. (1992) 261:50–55.
   PubMed Web of Science ®Google Scholar
• SPEEG KV, MALDONADO AL: Effect of the nonimmuno-suppressive cyclosporin analog SDZ PSC-833 on colchicine and doxorubicin biliary secretion by the rat in vivo. Cancer Chemother. Pharmacol. (1994) 34:133–136.
   PubMed Web of Science ®Google Scholar
• DESRAYAUD S, GUNTZ P, SCHERRMANN JM, LEMAIRE M: Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine. Life Sci. (1997) 61:153–163.
   PubMed Web of Science ®Google Scholar
• SAITHOH I, OHTSU T, FUJII H et al.: A Phase 1 trial of intravenous SDZ PSC 833 in combination with doxorubicin as a modulator of MDR in cancer patients. 54th Ann. Meet. Jpn. Cancer Assoc. (Oct 3–5, Kyoto) (1995): Abstract 2178.
   Google Scholar
• ERLICHMAN C, MOORE M, THIESSEN J, DE ANGELIS C, GOODMAN P, MANZO J: A Phase I trial of doxorubicin (DOX) and PSC 833, a modulator of multidrug resistance. Proc. Am. Soc. Clin. Oncol (1994) 13:134.
   Google Scholar
• ERLICHMAN C, MOORE MJ, THIESSEN J, DE ANGELIS G, GOODMAN P, MANZO J: A Phase I trial of doxorubicin (DOX) and PSC 833, a modulator of multidrug resistance (MDR). Anti-Cancer Drugs (1994) 5:42.
   Google Scholar
• OHTSU T, TANIGAWARA Y, FUJII H et al.: A Phase I trial of intravenous SDZ PSC 833 (PSC) in combination with doxorubicin (DOX) as a modulator of multidrug resistance (MDR) in cancer patients. Proc. Am. Soc. Clin. Oncol. (1996) 15:487.
   Google Scholar
• LEMON S, MEADOWS B, FOJO A, GOLDSPIEL B, BATES S: A Phase I study of infusional vinblastine with the p-glycoprotein antagonist PSC 833 in patients with metastatic cancer. Proc. Am. Soc. Clin. Oncol (1995) 14:479.
   Google Scholar
• FIELDS A, HOCHSTER H, RUNOWICZ C, SPEYER J, GOLDBERG G, COHEN C: SDZ PSC 833/paclitaxel in paclitaxel refractory ovarian carcinoma: a Phase II trial with renewed responses. Proc. Am. Soc. Clin. Oncol (1997) 16:351a.
   Google Scholar
• WESTERVELT P, WILLIAMS KM, ROSEN DM, EGORIN MJ, FRACASSO PM: A Phase I study of taxol and intravenous PSC 833 in patients with refractory solid tumors. Proc. Am. Soc. Clin. Oncol (1997) 16:254a.
   Google Scholar
• MAYER U, WAGENAAR E, DOROBEK B, BEIJNEN JH, BORST P, SCHINKEL AH: Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC 833. J. Clin. Invest. (1997) 100: 2430–2436.
   PubMed Web of Science ®Google Scholar
• ••A challenge to the in vivo potential of valspodar.
   Google Scholar
• PEIN F, PINKERTON R, RUBIE H, STEVENS M, PEARSON A, DOZ F: A Phase I trial of oral SDZ PSC-833 in combina-tion with a rapid schedule of intravenous (IV) etoposide in children with relapsing and/or refrac-tory solid tumors. A joint GP-SFOP/NAG-UKCCSG study with Sandoz Pharma. Proc. Am. Soc. Clin. Oncol. (1997) 16:528a.
   Google Scholar
• PAUL C, TIDEFELT U, GRUBER A et al.: The P-glycoprotein inhibitor (PgP) PSC 833 increases the intracellular concentrations of daunorubicin (DNR) in vivo in patients with PgP positive AML. Blood (1997) 90:182A.
   PubMedGoogle Scholar
• ADVANI R, HAUSDORFF J, FISHER GA, HALSEY J, LUM BL, LITCHMAN M: A Phase I trial of doxorubicin, paclitaxel and PSC 833, a potent modulator of multidrug resistance. Proc. Am. Soc. Clin. Oncol. (1997) 16:218a.
   Google Scholar
• DALTON W, GREIPP P, GREENBERG P, STIFF P, BALLESTER 0, FRIEDENBERG W: Phase I study of the chemosensitizer SDZ PSC 833 in combination with VAD chemotherapy to reverse multidrug resistance. Blood (1996) 88:662A.
   Google Scholar
• SIKIC BI: Reversing multidrug resistance with the nonimmunosuppressive cyclosporin PSC 833. 1st. Chem other. Found. Symp. Innovative Cancer Ther. Tomorrow. 1–3 Nov. New York, USA (1995). Abstract 55.
   Google Scholar
• KRISTENSEN G, BAEKELANDT M, HOLM R, LEHNE G, HESTDAL K, LABURTE C: Evaluation of PSC 833 in combination with doxorubicin / cisplatin in refrac-tory ovarian cancer. Anti-Cancer Drugs (1994) 5:Abstract 147.
   Google Scholar
• COBB P, BURRIS H, WEISS G et al.: Phase I trial of PSC-833 and doxorubicin, vincristine, cyclophospha-mide, and prednisone (DVCP) in patients with refrac-tory non-Hodgkin's lymphoma. Proc. Am. Soc. Clin. Oncol. (1995) 14:484.
   Google Scholar
• COBB P, BURRIS H, WEISS G et al: Phase I trial of PSC 833 and doxorubicin, vincristine, cyclophosphamide, and prednisone (DVCP) in patients with refractory non-Hodgkin's lymphoma. Blood (1994) 84:167a.
   Web of Science ®Google Scholar
• LIST AF, KARANES C, DORR R, SPIER C, GROGAN T, GREER J. Modulation of anthracycline resistance in poor-risk acute myeloid leukemia (AML) with SDZ PSC-833: results of a Phase I/II multicenter study. Blood (1996) 88:292a.
   Google Scholar
• LILIEMARK J, BJORKHOLM M, UDEN AM, HAST R, PAUL C, SIMONSSON B. A Phase I/II study of SDZ PSC 833 (PSC) in combination with daunorubicin (D) and cytarabine in refractory acute myelogenous leukemia (AML). Blood (1996) 88:216A.
   Google Scholar
• ADVANI R, SABA H, ROWE JM, TALLMAN M, WIERNIK P, RAMEK J: Treatment of refractory/relapsed AML with P5C833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC). Blood (1996) 88:215A.
   Google Scholar
• BAEKELANDT M, COVELLI A, TROPE C, KEISTENSEN G: Phase I/II trial of cisplatin and doxorubicin with SDZ PSC 833 in patients with refractory ovarian cancer. Proc. Am. Soc. Clin. Oncol. (1997) 16:216a.
   Google Scholar
• CEFALU WT, PARDRIDGE WM: Restrictive transport of a lipid soluble peptide (cyclosporin) through the blood-brain barrier. J. Neurochem. (1985) 45:1954–1956.
   PubMed Web of Science ®Google Scholar
• MASON J: Pharmacology of cyclosporine (Sandim-mune). VII. Pathophysiology and toxicology of cyclosporin in humans and animals. Pharmacol. Rev. (1989) 42:423–434.
   Google Scholar
• KLOCKGETHER T, EVERT B: Genes involved in heredi-tary ataxias. Trends Neurol. Sci. (1998) 21:413–418.
   PubMed Web of Science ®Google Scholar
• LUKER GD, FRACASSO PM, DOBKIN J, PIWNICA-WORMS: Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m- in vivo. J. Nucl. Med. (1997) 38:369–372.
   PubMed Web of Science ®Google Scholar
• •Evidence of valspodar-mediated inhibition of Pgp function in vivo.
   Google Scholar
• GOSLAND M, TSUBOI C, HOFFMAN T, GOODIN S, VORE: 1713-estradiol glucuronide: an inducer of cholestasis and a physiological substrate for the multidrug resistance transporter. CancerRes. (1993) 53:5382–5385.
   Web of Science ®Google Scholar
• VORE M, HOFFMAN T, GOSLAND M: ATP-dependent transport of B-estradiol 17-(0-D-glucuronide) in rat canalicular membrane vesicles. Am. J. Physiol. (1996) 271:G791–798.
   PubMed Web of Science ®Google Scholar
• LIU Y, HUANG L, HOFFMAN T, GOSLAND M, VORE M: MDR1 substrates/modulators protect against 0-estradio1-170-D-glucuronide cholestasis in rat liver. Cancer Res. (1996) 56:4992–4997.
   PubMed Web of Science ®Google Scholar
• AICHER L, MEIER G, NORCROSS AJ et al.: Decrease in kidney calbindin-D 28kDa as a possible mechanism mediating cyclosporine A- and FK-506-induced calciuria and tubular mineralization [published erratum appears in Biochem. Pharmacol. (1997) 53:1945]. Biochem. Pharmacol. (1997) 53:723–731.
   Google Scholar
• SCHINKEL AH, MOL CAAM, WAGENAAR E, VAN DEEMTER L, SMIT JJM, BORST P: Multidrug resistance and the role of P-glycoprotein knockout mice. Eur. J. Cancer Part A (1995) 31:1295–1298.
   Google Scholar
• DIDIER AD, LOOR F: Decreased biotolerability for ivermectin and cyclosporin A in mice exposed to potent P-glycoprotein inhibitors. Int. J. Cancer (1995) 63:263–267.
   PubMed Web of Science ®Google Scholar
• •Evidence of valspodar-mediated inhibition of Pgp function in vivo.
   Google Scholar
• DRION N, LEMAIRE M, LEFAUCONNIER JM, SCHERRMANN JM: Role of P-glycoprotein in the blood-brain transport of colchicine and vinblastine. J. Neurochem. (1996) 67:1688–1693.
   PubMed Web of Science ®Google Scholar
• KUSUHARA H, SUZUKI H, TERASAKI T, KAKEE A, LEMAIRE M, SUGIYAMA Y: P-Glycoprotein mediates the of quinidine across the blood-brain barrier. J. Pharmacol. Exp. Ther. (1997) 283:574–580.
   PubMed Web of Science ®Google Scholar
• WACHER VJ, WU CY, BENET LZ: Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinogen. (1995) 13:129–134.
   PubMed Web of Science ®Google Scholar
• TIBERGHIEN F, TRABER R, WENANDY T, DIDIER A, LOOR F: The Cyclosporin-like cyclopeptolide SDZ 214–103. Structure-Activity Relationships for the inhibition of model 7TM G-protein coupled receptor and 12TM ABC-transporter. (1999) (Manuscript in preparation).
   Google Scholar
• TIBERGHIEN F, TAKESATO K, KUROME T, DIDIER A, LOOR F: Aureobasidins: Structure-Activity Relation-ships for the inhibition of the human MDR1 P-glycoprotein ABC-transporter. (1999) Manuscript in preparation. Loor
   Google Scholar